Invivo Antagonist activity at Maxadilan-induced Sprague-Dawley rat assessed as reduction in Maxadilan-induced blood flow at 0.3 mg/kg,sc measured after 45 mins
Antagonist activity at PAC1R in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
Antagonist activity at PAC1R in rat RG2 cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
Antagonist activity at PAC1R in human SH-SY5Y cells assessed as inhibition of Maxadilan-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay
Antagonist activity at PAC1R in rat RG2 cells assessed as inhibition of Maxadilan-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay